Blessy Jacob
Primary Care · Houston, TXNPI 1831499029
Payments from drug & device makers
Across 79 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$188
- Lilly USA, LLC$145
- AbbVie$131
- Merck$98
- GSK$90
- Pfizer$89
- plus $638 from 14 others
What the payments were for
- Food & beverage$1,378100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $188 |
| Lilly USA, LLC | 7 | $145 |
| AbbVie | 8 | $131 |
| Merck | 7 | $98 |
| GSK | 5 | $90 |
| Pfizer | 6 | $89 |
| Boehringer Ingelheim | 6 | $88 |
| Novartis | 5 | $80 |
| Sanofi-aventis U.S. LLC | 4 | $75 |
| Abbott | 3 | $59 |
| Novo Nordisk | 3 | $50 |
| Bayer | 3 | $49 |
| Astellas Pharma US Inc | 2 | $44 |
| Johnson & Johnson | 2 | $38 |
| Boston Scientific | 2 | $36 |
| Exact Sciences | 1 | $29 |
| Edwards Lifesciences | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $24 |
| Morphosys, US Inc. | 1 | $18 |
How this compares
$1,378 in reported general payments places this provider in the 75th percentile of 563 primary care providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 18 | $16,212 |
| OzempicSemaglutide | 12 | $14,687 |
| Rosuvastatin Calcium | 42 | $980 |
| Atorvastatin Calcium | 102 | $750 |
| Pregabalin | 15 | $702 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 29 | $505 |
| Nifedipine ErNifedipine | 18 | $412 |
| Pantoprazole Sodium | 27 | $405 |
| ClopidogrelClopidogrel Bisulfate | 29 | $395 |
| Duloxetine Hcl | 26 | $363 |
| Losartan Potassium | 36 | $327 |
| Glipizide-MetforminGlipizide/Metformin Hcl | 12 | $325 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 35 | $291 |
| Amlodipine Besylate | 66 | $258 |
| Doxycycline Hyclate | 34 | $248 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $88 | $16,21218 claims |
| Novo NordiskOzempic | $50 | $14,68712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 563 primary care providers in Texas.
Other primary care in Houston
- Mary GibbensHouston$42K
- Joanna LarsonHouston$7K
- Mei ChenHouston$4K
- Catherine PenceHouston$3K
- Phillip GulleySan Antonio$23K
- Herbert BautistaDallas$14K
- Roxana RoposGrapevine$13K
- Brandi JoynerLongview$12K
- Steven ParisAustin$10K
- Hope OdomCollege Station$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.